We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate‐to‐severe psoriasis.
- Authors
Ovejero‐Benito, M.C.; Muñoz‐Aceituno, E.; Sabador, D.; Reolid, A.; Llamas‐Velasco, M.; Prieto‐Pérez, R.; Abad‐Santos, F.; Daudén, E.
- Abstract
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis We recruited 120 patients with moderate-to-severe plaque psoriasis from the Dermatology Department of "Hospital Universitario La Princesa" in Madrid treated with etanercept (52.5%), adalimumab (30.8%) and/or ustekinumab (16.7%) (Fig. a). 50/120 patients were subjected to a second biological drug cycle and 13 to a third cycle (total 183 cycles). New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
- Subjects
BIOTHERAPY; DRUG therapy; PSORIATIC arthritis; PSORIASIS
- Publication
Journal of the European Academy of Dermatology & Venereology, 2020, Vol 34, Issue 6, pe271
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.16256